FREMONT, Calif. – Nitinol Devices & Components (NDC) today announced the appointment of Dean Schauer as its President and CEO, effective September 1, 2013.
“We are delighted to welcome someone as singularly qualified as Dean to take NDC to the next stage of its development,” said Tom Duerig, current President and CEO. “Dean is an experienced senior executive in integrated outsourced engineering and manufacturing services and brings more than 20 years of relevant industry experience to this role. He has held a number of increasingly senior positions at Accellent Inc. and most recently served as its Executive Vice President and General Manager of their Cardio & Vascular Group. I personally am looking forward to helping Dean move the company forward while engaging in a more focused technical role within NDC.” Dean will also join NDC’s board of directors, currently chaired by Rick Charpie of Ampersand Capital Partners.
“I am really excited about joining NDC in this leadership role and I am grateful to Tom and the Board of Directors for affording me this wonderful opportunity,” commented Dean Schauer. “I am looking forward to working closely with the entire NDC Team to grow our Company and am delighted that Tom will continue as a key member of our Board of Directors and a critical leader within NDC’s technical staff.”
About NDC
NDC is an engineering-driven contract manufacturer of Nitinol-based medical devices headquartered in Fremont, CA, USA. Focused on serving the needs of major medical OEM’s, NDC provides manufacturing, research, development, regulatory and technical support on all aspects of shape memory and superelastic Nitinol products.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
